Matthew M. Gubin

10.8k citations

22 papers · 5.1k indexed · 3 hit papers · h-index 17

Immunology top 0.5%
- Immunotherapy and Immune Responses 9
- Immune Cell Function and Interaction 7
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 10
- CAR-T cell therapy research 3
Cancer Research top 1%
Molecular Biology top 5%
- RNA Research and Splicing 8
- RNA modifications and cancer 6
- RNA and protein synthesis mechanisms 6
- vaccines and immunoinformatics approaches 2
Biological Psychiatry top 10%

Co-authors: Robert D. Schreiber Mark J. Smyth Deepak Mittal Takuro Noguchi Chih‐Hao Chang Michael D. Buck Erika L. Pearce Gerritje J. W. van der Windt
Cited by: Immunology Oncology Cancer Research
Partner nations: United States Singapore Australia

In The Last Decade

Matthew M. Gubin

22 papers receiving 5.0k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2015 Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Tumor neoantigens: building a framework for personalized cancer immunotherapy
2014 New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape

Peers

Countries citing papers authored by Matthew M. Gubin

Since Specialization

Citations

This map shows the geographic impact of Matthew M. Gubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew M. Gubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew M. Gubin more than expected).

Fields of papers citing papers by Matthew M. Gubin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew M. Gubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew M. Gubin. The network helps show where Matthew M. Gubin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Matthew M. Gubin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew M. Gubin Line = papers co-authored together Matthew M. Gubin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy Sunita Keshari,Alexander S. Shavkunov,Qi Miao,Akata Saha,Tomoyuki Minowa,Martina Molgora,Charmelle D. Williams,Mehdi Chaib,Anna M. Highsmith,Josué E. Pineda,Sayan Alekseev,Elise Alspach,Kenneth H. Hu,Marco Colonna,Kristen E. Pauken,Ken Chen,Matthew M. Gubin	2024	6
2	Cancer Immunoediting in the Era of Immuno-oncology Matthew M. Gubin,Matthew D. Vesely	2022	75
3	BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy Avery J. Salmon,Alexander S. Shavkunov,Qi Miao,Nicholas N. Jarjour,Sunita Keshari,Ekaterina Esaulova,Charmelle D. Williams,Jeffrey P. Ward,Anna M. Highsmith,Josué E. Pineda,Reshma Taneja,Ken Chen,Brian T. Edelson,Matthew M. Gubin	2022	24
4	High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy Matthew M. Gubin,Ekaterina Esaulova,Jeffrey P. Ward,Olga Malkova,Daniele Runci,Pamela Wong,Takuro Noguchi,Cora D. Arthur,Wei Meng,Elise Alspach,Ruan F.V. Medrano,Catrina C. Fronick,Michael Fehlings,Evan W. Newell,Robert S. Fulton,Kathleen C. F. Sheehan,Stephen T. Oh,Robert D. Schreiber,Maxim N. Artyomov	2018	275
5	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape Takuro Noguchi,Jeffrey P. Ward,Matthew M. Gubin,Cora D. Arthur,Sang Hun Lee,Jasreet Hundal,M. J. Selby,Robert F. Graziano,Elaine R. Mardis,Alan J. Korman,Robert D. Schreiber	2017	242
6	Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells Michael G. Fehlings,Yannick Simoni,Hweixian Leong Penny,Étienne Becht,Chiew Yee Loh,Matthew M. Gubin,Jeffrey P. Ward,Siew Cheng Wong,Robert D. Schreiber,Evan W. Newell	2017	91
7	Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology Keystone Symposia Meeting Summary Matthew M. Gubin	2017	3
8	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer Jeffrey P. Ward,Matthew M. Gubin,Robert D. Schreiber	2016	178
9	Abstract A001: Tumor-specific mutant antigens in cancer immunotherapy Matthew M. Gubin,Jeffrey P. Ward,Takuro Noguchi,Xiuli Zhang,Cora D. Arthur,Willem-Jan Krebber,Gwenn E. Mulder,Cornelis J.M. Melief,William E. Gillanders,Maxim N. Artyomov,Elaine R. Mardis,Robert D. Schreiber	2016	3
10	Transcriptomic-Wide Discovery of Direct and Indirect HuR RNA Targets in Activated CD4+ T Cells Patsharaporn Techasintana,J. Wade Davis,Matthew M. Gubin,Joseph Magee,Ulus Atasoy	2015	12
11	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progressionbreakdown → Chih‐Hao Chang,Jing Qiu,David O’Sullivan,Michael D. Buck,Takuro Noguchi,Jonathan D. Curtis,Qiongyu Chen,Mariel Gindin,Matthew M. Gubin,Gerritje J. W. van der Windt,Elena Tonc,Robert D. Schreiber,Edward J. Pearce,Erika L. Pearce	2015	2297
12	Tumor neoantigens: building a framework for personalized cancer immunotherapybreakdown → Matthew M. Gubin,Maxim N. Artyomov,Elaine R. Mardis,Robert D. Schreiber	2015	465
13	Conditional Knockout of the RNA-Binding Protein HuR in CD4+ T Cells Reveals a Gene Dosage Effect on Cytokine Production Matthew M. Gubin,Patsharaporn Techasintana,Joseph Magee,Garrett M. Dahm,Robert Calaluce,Jennifer L. Martindale,Maryln S. Whitney,Craig L. Franklin,Cindy Besch‐Williford,John W. Hollingsworth,Kotb Abdelmohsen,Myriam Gorospe,Ulus Atasoy	2014	32
14	New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escapebreakdown → Deepak Mittal,Matthew M. Gubin,Robert D. Schreiber,Mark J. Smyth	2014	1078
15	Posttranscriptional Gene Regulation of IL-17 by the RNA-Binding Protein HuR Is Required for Initiation of Experimental Autoimmune Encephalomyelitis Jing Chen,Jason A. Cascio,Joseph Magee,Patsharaporn Techasintana,Matthew M. Gubin,Garrett M. Dahm,Robert Calaluce,Shiguang Yu,Ulus Atasoy	2013	70
16	Incisional hernia recurrence through genomic profiling: a pilot study Robert Calaluce,J. Wade Davis,Sharon L. Bachman,Matthew M. Gubin,James A. Brown,Joseph Magee,Timothy S. Loy,Bruce Ramshaw,Ulus Atasoy	2012	26
17	Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip Garrett M. Dahm,Matthew M. Gubin,Joseph Magee,Patsharaporn Techasintana,Robert Calaluce,Ulus Atasoy	2012	17
18	Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip Garrett M. Dahm,Matthew M. Gubin,Joseph Magee,Patsharaporn Techasintana,Robert Calaluce,Ulus Atasoy	2012	4
19	The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer Robert Calaluce,Matthew M. Gubin,J. Wade Davis,Joseph Magee,Jing Chen,Yuki Kuwano,Myriam Gorospe,Ulus Atasoy	2010	51
20	Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis Matthew M. Gubin,Robert Calaluce,J. Wade Davis,Joseph Magee,Connie S. Strouse,Daniel P. Shaw,Lixin Ma,Ashley N. Brown,Timothy J. Hoffman,Tammy L. Rold,Ulus Atasoy	2010	50

About Matthew M. Gubin

Matthew M. Gubin is a scholar working on Immunology, Oncology and Cancer Research, having authored 22 papers that have together received 5.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (10 papers), Immunotherapy and Immune Responses (9 papers), RNA Research and Splicing (8 papers), Immune Cell Function and Interaction (7 papers), RNA modifications and cancer (6 papers), RNA and protein synthesis mechanisms (6 papers), CAR-T cell therapy research (3 papers) and vaccines and immunoinformatics approaches (2 papers). The work is most often cited by research in Immunology (2.8k citations), Oncology (2.7k citations) and Cancer Research (1.2k citations). Matthew M. Gubin has collaborated with scholars based in United States, Singapore and Australia. Frequent co-authors include Robert D. Schreiber, Mark J. Smyth, Deepak Mittal, Takuro Noguchi, Chih‐Hao Chang, Michael D. Buck, Erika L. Pearce, Gerritje J. W. van der Windt, Qiongyu Chen and David O’Sullivan.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact